Here, we report that LMK235, a class I and histone deacetylase (HDAC6)-preferential HDAC inhibitor, reduces hypertension via inhibition of vascular contraction and vessel hypertrophy. Angiotensin II-infusion mice and spontaneously hypertensive rats (SHRs) were used to test the anti-hypertensive effect of LMK235. Daily injection of LMK235 lowered angiotensin II-induced systolic blood pressure (BP). A reduction in systolic BP in SHRs was observed on the second day when SHRs were treated with 3 mg/kg LMK235 every 3 days. However, LMK235 treatment did not affect angiotensin-converting enzyme 1 and angiotensin II receptor mRNA expression in either hypertensive model. LMK235, acting via the nitric oxide pathway, facilitated the relaxing of vascular contractions induced by a thromboxane A2 agonist in the rat aortic and mesenteric artery ring test. In addition, LMK235 increased nitric oxide production in HUVECs and inhibited the increasing of aortic wall thickness in both animal hypertensive models. LMK235 decreased the enhanced cell cycle-related genes cyclin D1 and E2F3 in angiotensin II-infusion mice and restored the decreased p21 expression. In addition, LMK235 suppressed calcium calmodulin-dependent protein kinase II (CaMKII) α, which is related to vascular smooth muscle cell proliferation. 
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| INTRODUC TI ON
Hypertension may damage a variety of organs and leads to complications, such as brain stroke, retinopathy, atherosclerosis, kidney failure, coronary heart diseases and heart failure. 1 HDAC1 and HDAC5 protein levels were increased in the lungs of human idiopathic pulmonary hypertension patients and hypoxiainduced rats. 5 There are several reports on the relevance of HDACs to the development of hypertension. Enhanced HDAC6 enzyme activity was shown in chronic hypertension such as deoxycorticosterone acetate (DOCA)-salt-induced hypertensive rats. 6 Kidney damage is closely related to hypertension. HDAC7 plays an important role in the regulation of the epithelial Na (+) channel (ENaC) in the kidney via ubiquitination.
7
HDAC3 plays a critical role in the regulation of hypertension, including in the deacetylation of mineralocorticoid receptor (MR) and its target gene transcriptional activity. as a class IIa-preferential hydroxamate-based HDAC inhibitor.
12
In the present study, we sought to investigate whether LMK235
could suppress high BP in angiotensin II-infusion mice and in essential hypertensive rats. Our results suggest that LMK235 may be a useful pharmacological agent for the treatment of hypertension through relaxation of vascular contraction or attenuation of vascular hyperplasia although LMK235 does not act as a class IIa selective HDAC inhibitor.
| MATERIAL S AND ME THODS

| Hypertensive animal protocol
All animal procedures were approved by the Animal Experimental from Charles River (Yokohama, Japan). Rats were intraperitoneally administered LMK235 or vehicle every 3 days for 2 weeks (n = 4 per group).
| BP measurements
Systolic BP was measured by the tail-cuff method (Visitech Systems, BP-2000). Animals (mice and rats) were trained to allow for the measuring of BP before administration of the drug.
Animals were trained to enter the holder at the same time more than three times a week to measure BP. For angiotensin II-mice, systolic BP was measured when the mice were awake the day before they are killed. For SHRs, systolic BP was measured daily for 2 weeks.
| Isometric tension measurement
Male Sprague-Dawley rats were purchased from Orient Bio (Gyeonggi-do, South Korea 
| Histology and immunohistochemistry
The paraffin-embedded tissues were cut into 3-μm-thick sections, deparaffinized with xylene and then rehydrated with graded alcohol.
Haematoxylin and eosin (H&E) staining was performed as described, with slight modifications. 15 The arterial wall thickness was measured using NIS Elements Software (Nikon, Japan). with EGM-2 bullet kit (Lonza, Walkersville, MD) and maintained at 37°C under 5% CO 2 . Cells were cultured for 5-7 passages.
| Cell culture
| Nitric oxide production in HUVECs
We used a nitric oxide-sensitive fluorescence probe, 4-amino-5-meth- 
| MTT assay
| Reagents
LMK235 was obtained from Prof. Thomas Kurz (Heinrich-Heine Universität Düsseldorf, Germany) and synthesized according to a previously published protocol. 12 HDAC5 small interfering RNA (siRNA) was purchased from Dharmacon (Lafayette, CO, USA).
Sicontrol was purchased from Bioneer (Daejeon, South Korea).
The pCMV-SPORT6-CaMKIIα clone was provided from Korea
Human Gene Bank, Medical Genomics Research Center, KRIBB, Korea.
| HDAC enzyme activities
Enzyme activity measurements of class I and IIa HDACs were performed using a cell-free system and according to a method previously described. 16 We used fluorogenic HDAC1 (#50061), values (50% activity). 
| Transfection
| Real-time reverse transcription-polymerase chain reaction
Total RNA from aortic tissue was isolated with TRIzol reagent (Invitrogen Life Technologies), and 1 μg of RNA was used for the reverse transcription reaction with TOPscript RT DryMIX (Enzynomics, South Korea). Quantification of mRNA levels was performed with the SYBR Green PCR kit (Enzynomics, South Korea). The PCR primers used in this study are shown in Table S1 .
| Western blot analysis
Cells were lysed in RIPA lysis buffer [150 mmol/L NaCl, 1%
Triton X-100, 1% sodium deoxycholate, 50 mmol/L Tris-HCl pH (1:1000), anti-HDAC1 (1:1000), anti-HDAC2 (1:1000), anti-HDAC4
(1:1000) and anti-HDAC5 (1:1000). As secondary antibodies, horse radish peroxidase-linked antimouse or anti-rabbit antibodies were used. Protein bands were visualized using Immobilon Western Detection Reagents (Millipore, Billerica, MA, USA). The Bio-ID software was used to quantify protein expression (Vilber Lourmat, Eberhardzell, Germany).
| Immunoprecipitation
In order to investigate the interaction between HDAC4/5/6 and class I HDACs, we performed immunoprecipitation in VSMCs.
Protein was separated using 0.5% NP lysis buffer ( termination, 25 μg of total protein were subjected to SDS-PAGE.
Immunoblotting was performed using anti-HDAC1, anti-HDAC2, anti-HDAC3, anti-HDAC4, anti-HDAC5 and anti-HDAC6. 
| Statistical analysis
All the data are expressed as the mean ± standard error (SE). Data analysis was performed using ANOVA with a Bonferroni post hoc test when three or more groups were compared. The statistics were analysed using GraphPad Prism version 5 and a P < 0.05 was considered significant.
| RE SULTS
| LMK235 reduces high BP in angiotensin IIinduced hypertensive mice and SHRs
We recently demonstrated that MC1568 (class II HDAC inhibitor)
but not tubastatin A (HDAC6 selective inhibitor) lowered elevated BP in angiotensin II-induced hypertensive mice. 11,17 Therefore, we
suggested that HDAC4 and HDAC5 may be related to the development of hypertension. We thus tested the effect of LMK235, a previously described HDAC4-and HDAC5-selective inhibitor, at different dosages in two hypertension animal models. First, we examined the anti-hypertensive effect of LMK235 in angiotensin II-induced hypertension. We found that daily LMK235 administration (1 mg/kg/ day) is sufficient to lower systolic BP in angiotensin II-infusion mice ( Figure 1A ). In addition, a moderate dosage of 3 mg/kg/day LMK235
showed a similar effect on the inhibition of high BP ( Figure 1B) . Next, we investigated the BP lowering effect of LMK235 on SHRs. LMK235
was administrated to SHRs every 3 days, and systolic BP was measured daily. Before LMK235 treatment, SHRs showed high systolic BP compared to WKY controls. On the next day after LMK235 injection, a reduction in systolic BP relative to SHRs was observed. At 2 days after LMK235 treatment, systolic BP was significantly lowered in SHRs. At 3 days after LMK235 administration, systolic BP was restored to a comparable level to vehicle-treated SHRs ( Figure 1C ). The cycle-pattern of systolic BP repeatedly occurred. LMK235 showed a 2-day long-lasting BP lowering effect.
| Expression of ACE1 and AT1 mRNA are not reduced by LMK235
To determine whether LMK235 can regulate hypertension through the RAAS, we examined the mRNA levels of angiotensin II type 1 receptor (AT1) and angiotensin-converting enzyme 1 (ACE1) in the aorta from angiotensin II-infusion mice and SHRs. AT1 transcript levels were significantly increased in angiotensin II-infusion mice.
The increase was not reduced by LMK235 treatment (Figure 2A ).
ACE1 mRNA levels were not up-regulated in angiotensin II-infusion mice ( Figure 2B ). We observed that AT1 mRNA levels were significantly enhanced in the aortas of SHRs, but they were not affected by LMK235 administration ( Figure 2C ). ACE1 mRNA was not increased in the aortas of SHRs ( Figure 2D ).
| LMK235 induces vasorelaxation via the nitric oxide pathway
To elucidate whether the anti-hypertensive effect of LMK235 is related to vascular contraction, we investigated vascular contraction-relaxation in rat thoracic aortas and mesenteric arter- The expressions of AT1 and ACE1 mRNA levels were assessed by qRT-PCR in aortas from SHRs. **P < 0.01 vs WKY control; NS indicates not significant in endothelium-intact or endothelium-denuded rat aortic rings.
As shown in Figure 3A (open circles), LMK235 treatment dose dependently reduced U46619-induced vasoconstriction in endothelium-intact aortic rings. In addition, LMK235 also inhibited U46619-induced vasoconstriction in endothelium-denuded aortic rings ( Figure 3A , black circles). However, the relaxation effect of LMK235 was stronger in endothelium-intact aortic rings than in endothelium-denuded aortic rings. The vascular relaxation effect of LMK235 showed similar results in rat mesenteric arteries ( Figure 3B ). In order to determine whether LMK235 relaxes vascular contraction via activation of the nitric oxide pathway, we pretreated mesenteric artery rings with a nitric oxide synthase blocker, L -NAME (100 μmol/L), or vehicle for 30 minutes.
LMK235 was cumulatively added to U46619-treated mesenteric vessels. Pretreatment with L -NAME inhibited vascular relaxation, which was induced by cumulative addition of LMK235 ( Figure 3B ).
To assess whether the rat ring test results could be replicated in vitro, we measured nitric oxide production in HUVECs. LMK235
increased nitric oxide production in HUVECs, and this increase was reduced by L -NAME treatment ( Figure 3C ).
F I G U R E 3
Pretreatment with L -NAME reduces LMK235-mediated vasorelaxation in rat mesenteric arteries as well as LMK235-induced nitric oxide production in HUVECs. 
| LMK235 decreases the increased aortic wall thickness in hypertension
Previously, we demonstrated that MC1568 attenuates vascular hypertrophy and hyperplasia both in angiotensin II-induced hypertensive mice and VSMCs. 11 To determine whether LMK235 can affect arterial wall thickness, we measured wall thickness after H&E staining. As shown in Figure 4A ,B, LMK235 treatment for 1 week with 3 mg/kg/ day completely inhibited the increased aortic wall thickness in angiotensin II-infusion mice. Similar results were observed in the SHR aortas ( Figure 4C,D) . Aortic wall thickness of SHRs was increased compared to WKY, and this increase was reduced by LMK235 treatment. 
F I G U R E 4 LMK235 decreases
| LMK235 decreases the expression of cell cycle genes and calcium CaMKII α in angiotensin IIinfusion mice
To identify whether arterial wall thickness may be mediated by VSMC growth, we examined the cell cycle-related molecules using qRT-PCR. LMK235 administration significantly suppressed the expression of cyclin D1 and E2F3 mRNA levels ( Figure 5A,B) . Next, we determined the expression of p21, a cell cycle arrest gene. We found that p21 transcript levels were decreased in the aortas of angiotensin II-infusion mice compared to the control. LMK235 restored the repressed p21 expression ( Figure 5C ). Calcium calmodulin-dependent kinase II (CaMKII) has been reported to be related to the proliferation of VSMCs. 18, 19 In addition, we have reported that the overexpression of the CaMKIIα isoform increases VSMC proliferation. 11 Therefore, we determined the expression of CaMKIIα in angiotensin II-infusion mice. As shown in Figure 5D , LMK235
significantly reduced the angiotensin II-induced CaMKIIα mRNA levels.
| LMK235 decreases CaMKIIα overexpressioninduced cell cycle genes and class I/IIa HDACs
In the present study, we confirmed that overexpression of CaMKIIα 
| HDAC4 and 5 interact endogenously with class I HDACs in VSMCs
To investigate whether inhibition of HDAC4/5 by LMK235 is caused by recruiting class I HDACs, we performed immunoprecipitation in VSMCs. HDAC4 interacted endogenously with HDAC1, HDAC2 and HDAC3 ( Figure 7 ). HDAC5 was strongly associated with HDAC1 and HDAC2, but interacted weakly with HDAC3. However, HDAC6 did not bind to HDAC1, HDAC2 or HDAC3.
| Knockdown of HDAC5 attenuates CaMKIIα overexpression-induced cell cycle genes
To examine whether HDAC5 can regulate CaMKIIα-induced expression of cell cycle genes, knockdown of HDAC5 was performed.
HDAC5 siRNA successfully reduced the endogenous HDAC5 transcript levels in A10 cells ( Figure 8A ). However, HDAC5 siRNA did not affect the overexpression of CaMKIIα ( Figure 8B ). Transfection of HDAC5 siRNA completely inhibited the mRNA levels of HDAC5
induced by the overexpression of CaMKIIα ( Figure 8C ). In addition, siHDAC5 decreased cyclin D1 mRNA levels induced by overexpression of CaMKIIα ( Figure 7D ).
| D ISCUSS I ON
We investigated the anti-hypertensive effect of LMK235 in two hypertension models, angiotensin II-infusion mice and SHRs. In this study, we first demonstrated that LMK235 attenuates the enhanced systolic BP in both animal models. Angiotensin II-induced hypertension was effectively reduced by 7-day daily treatment with 1 mg/kg or 3 mg/kg LMK235. However, SHRs did not exhibit a hypertension lowering effect with LMK235 at a dosage of 1 mg/ kg/day (data not shown). Thus, we examined the effect of 3 mg/ kg/day of LMK235 on SHRs. A BP-lowering effect of LMK235 was observed upon injection once every 3 days rather than daily injection. In the present study, the highest suppression by LMK235 was GAPDH was used as a loading control. The amount of protein expression was quantified by densitometry. *P < 0.05 vs empty vector; # P < 0.05, ## P < 0.01 and ### P < 0.001 vs CaMKIIα transfection group observed 2 days after injection. On the third day, BP was restored to the level of the WKY controls. This result suggests that daily administration of LMK235 as an anti-hypertensive medicine is not necessary and could be replaced by administration once every 2 days. In accordance with our study, other previous studies have shown that valproic acid, a class I and class IIa HDAC inhibitor, attenuated BP in SHRs or DOCA-salt-induced hypertensive rats. 8, 20 In addition, Usui et al demonstrated that the pan-HDAC inhibitor trichostatin A (TSA) decreased systolic BP in SHRs. 10 However,
other research groups applied HDAC inhibitors in hypertensive rats for a longer period than our group.
We examined the relationship between hypertension and the RAAS. We found that LMK235 did not affect aortic ACE1 or AT1 in either hypertension model. Hence, in this study, LMK235 was unable to suppress the expression of ACE1 and AT1. Contrary to our results, Cardinale et al showed that cardiac AT1 mRNA levels were reduced by valproic acid in SHRs.
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How does LMK235 reduce high BP in our experiments? One possibility may be a relaxation of vasoconstriction. We observed that LMK235 showed a higher relaxation effect in endothelium-intact aortic rings than in endothelium-denuded aortic rings. This result implies that endothelium cells may play a pivotal role in the relaxation from vasoconstriction rather than VSMCs. Similar to our results, it was shown that TSA treatment reversed the augmented angiotensin II-induced contraction in the mesenteric artery of SHRs. 10 It was also observed that LMK235 induced vascular relaxation in resistance vessels such as mesenteric arteries, which affect hypertension.
Furthermore, L -NAME pretreatment reduced vasorelaxation and nitric oxide production ex vivo and in vitro, indicating that vascular relaxation by LMK235 is mediated by the nitric oxide pathway.
Arterial remodelling is associated with hypertension, and it was reported that angiotensin II stimuli induces VSMC hypertrophy and hyperplasia. 11, 21 In the present study, we showed that LMK235 reduces CaMKII is required for angiotensin II-mediated VSMC hypertrophy.
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Our previous study also demonstrated that CaMKIIα plays a critical role in VSMC hypertrophy and hyperplasia. The in vitro inhibitory activity of compound LMK235 against each HDAC isoform was determined using the HDAC Fluorogenic Assay Kit from BPS Bioscience. The IC 50 values were determined using 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μmol/L of an inhibitor. Trichostatin A (TSA) was used as the reference compound. ND indicates not determined.
